. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Benha University supportive Sites

Benha University Publications

Viewers: 1989

Benha University Publication:

Researcher Name Publication Title
Ahmed Tohamy Abd El-moneim Comparison between Continuous Thoracic Epidural and Ultrasound Guided Continuous Thoracic Paravertebral Block on Perioperative Analgesia and Hemodynamic Stability in Patients Undergoing Thoracotomy
Amal Abou El-Fadle Hassan Aly Comparison of cytokeratin 20 RNA and angiogenin in voided urine samples as diagnostic tools for bladder carcinoma
Amal Abou El-Fadle Hassan Aly Epigenetic alterations by methylation of< i> RASSF1A and< i> DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA
Amal Abou El-Fadle Hassan Aly Tissue inhibitor of matrix metalloproteinase-2 in nasopharyngeal carcinoma
Amal Abou El-Fadle Hassan Aly Usefulness of serum sFas and sFasL determinations as apoptogenic markers in liver disease
Amal Abou El-Fadle Hassan Aly Evaluation of bcl-2 and Transforming Growth Factor Alpha Oncoproteins in Patients with Chronic Hepatitis C Infection: Impact on Hepatocellular Carcinoma
Amal Abou El-Fadle Hassan Aly TRAIL: a non-invasive modality for proper staging of nasopharyngeal carcinoma
Amal Abou El-Fadle Hassan Aly EVALUATION OF SERUM LEVELS OF INTERLEUKIN-18, INTERFERON—F AND SOLUBLE FAS (CD 95) IN PATIENTS WITH PULMONARY TUBERCULOSIS
Amal Abou El-Fadle Hassan Aly RELATIONSHIP BETWEEN LEPTIN, NEUROPEPTIDE-Y AND SOME HORMONES IN WOMEN WITH POLYCYSTIC OVARY SYNDROME.
Amal Abou El-Fadle Hassan Aly Free maternal plasma DNA as a predictive marker for preeclampsia


First   <  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15  >  Last




. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .